positive novartis news

Novartis have announced the positive 1-year results from their Phase 3 studies, which are evaluating the efficacy and safety of Beovu in diabetic macular edema (DME). This is following possible safety concerns over the risk of side effects including retinal vasculitis, retinal vascular occlusion, blurred vision and cataracts.

Experts estimate that approximately 7.7 million Americans have diabetic retinopathy and of those, about 750,000 also have DME. The studies are a clear step forward “with the data demonstrating vision gains, fluid resolution and the potential for less frequent injections for eligible patients, we are one step closer to providing DME patients with a potential new treatment option.” J. Jill Hopkins Global Development Unit Head, Ophthalmology, Novartis Pharmaceuticals.

Ref: https://eyewire.news/articles/novartis-phase-3-beovu-data-show-potential-for-fluid-resolution-in-more-dme-patients-with-fewer-injections-versus-aflibercept/